中国2-5岁儿童接种7价肺炎球菌结合疫苗的免疫原性与安全性
该开放标签试验将2-5岁健康儿童按1:1随机分为PCV7组和Hib组,各接种单剂疫苗。接种6个月后,PCV7组7个血清型的IgG平均浓度和调理吞噬几何平均滴度均显著高于基线(P < .001),IgG ≥ 0.35 µg/mL的比例为90.0%至100%,且耐受性良好,无严重不良事件。
要点
- 单剂PCV7对2-5岁中国儿童具免疫原性,7个血清型抗体水平显著升高。
- 接种后IgG ≥ 0.35 µg/mL的比例达90.0%至100%。
- PCV7耐受性良好,研究期间无严重不良事件。
核心结论
- 单剂PCV7对中国2-5岁儿童具有免疫原性和安全性,原有抗体不影响疫苗应答。
研究设计与样本
- 开放标签试验,纳入2-5岁健康儿童,按1:1随机分为PCV7组和Hib组,各接种单剂疫苗,接种前和接种后6个月采集血样。
主要发现
- 接种单剂PCV7后6个月,PCV7组7个血清型的IgG平均浓度和调理吞噬几何平均滴度均显著高于基线(P < .001)。
- PCV7组IgG ≥ 0.35 µg/mL的比例范围为90.0%至100%。
- 抗体水平随年龄增长而升高,原有抗体未诱导对PCV7的低应答。
- Hib组6个月时抗体水平无显著差异或仅有轻微变化。
- PCV7在所有年龄组耐受性良好,研究期间无严重不良事件。
临床怎么用
- 提示单剂PCV7可用于2-5岁中国儿童,但中国2020年前仅批准PCVs用于2-15月龄儿童。
- 更广血清型覆盖的PCVs有望扩大肺炎球菌疾病保护范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The widespread use of pneumococcal conjugate vaccines (PCVs) has significantly decreased pneumococcal disease worldwide. However, China has not adopted PCVs in their national immunization schedules and had only approved these vaccines for children aged 2-15 months by 2020. METHODS: In an open-label trial, enrolled healthy children aged 2-5 years old were randomized 1:1 and divided into a 7-valent pneumococcal conjugate vaccine (PCV7) group and a Haemophilus influenzae type b conjugate vaccine (Hib) group. Children in the PCV7 group received a single dose of PCV7, and the Hib group received a single dose of Hib vaccine. Blood samples were collected before and 6 months after vaccination. Immunogenicity and safety of PCV7 were assessed at prespecified time points. RESULTS: Six months after a single dose of PCV7, children in the PCV7 group for all 7 serotypes, IgG mean concentrations (GMCs) and opsonophagocytic geometric mean titres (GMTs) were significantly higher (P < .001) than at baseline, and the proportion of IgG ≥ 0.35 µg/mL ranged from 90.0% to 100%. Although the antibody level increased with age, preexisting antibodies did not induce hyporesponsiveness to PCV7. In the Hib group, the antibody levels were not significantly different or had changed slightly at 6 months. PCV7 was well tolerated in all age groups, and no serious adverse events (AEs) emerged during this study. CONCLUSIONS: A single dose of PCV7 was immunogenic and safe for Chinese children aged 2-5 years, and the preexisting antibodies against the PCV7 serotypes did not change the response to vaccination. The findingssupported the effectiveness of PCV7 in this age group. PCVs with broader serotype coverage are expected to expand pneumococcal disease protection.
引用
- Wang J, Bai S, Zhou S, et al. Immunogenicity and safety of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 2-5 years in China. Vaccine. 2021. PMID: 33965257. doi:10.1016/j.vaccine.2021.04.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。